These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15839358)

  • 1. Muir-Torre syndrome: a case report and review of the literature.
    Pettey AA; Walsh JS
    Cutis; 2005 Mar; 75(3):149-55. PubMed ID: 15839358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry.
    Ponti G; Losi L; Di Gregorio C; Roncucci L; Pedroni M; Scarselli A; Benatti P; Seidenari S; Pellacani G; Lembo L; Rossi G; Marino M; Lucci-Cordisco E; Ponz de Leon M
    Cancer; 2005 Mar; 103(5):1018-25. PubMed ID: 15662714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muir-Torre syndrome: Diagnostic and screening guidelines.
    Jones B; Oh C; Mangold E; Egan CA
    Australas J Dermatol; 2006 Nov; 47(4):266-9. PubMed ID: 17034469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical follow-up and presence of visceral tumors in 12 patients with sebaceous gland tumors].
    Mercader P; García-Melgares ML; Roche E; Sánchez-Carazo JL; Alegre-de Miquel V
    Actas Dermosifiliogr; 2008 Sep; 99(7):532-9. PubMed ID: 18682166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An illustrative case of Muir-Torre syndrome: contribution of immunohistochemical analysis in identifying indicator sebaceous lesions.
    Marazza G; Masouyé I; Taylor S; Prins C; Gaudin T; Saurat JH; French LE
    Arch Dermatol; 2006 Aug; 142(8):1039-42. PubMed ID: 16924054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Muir-Torre syndrome and familial colorectal cancer: 2 families with molecular genetic analysis].
    Doré MX; Dieumegard B; Grandjouan S; Avril MF; Martinet C; Ducreux M; Lasser P; Bressac-de Paillerets B
    Ann Dermatol Venereol; 1999; 126(8-9):582-6. PubMed ID: 10530344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sebaceous neoplasms and the immunoprofile of mismatch-repair proteins as a screening target for syndromic cases.
    Boennelycke M; Thomsen BM; Holck S
    Pathol Res Pract; 2015 Jan; 211(1):78-82. PubMed ID: 25457183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MSH6 mutation in a family affected by Muir-Torre syndrome.
    Kacerovska D; Cerna K; Martinek P; Grossmann P; Michal M; Ricar J; Kazakov DV
    Am J Dermatopathol; 2012 Aug; 34(6):648-52. PubMed ID: 22814321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm.
    Abbas O; Mahalingam M
    J Cutan Pathol; 2009 Jun; 36(6):613-9. PubMed ID: 19515040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muir-Torre syndrome: a rare but important disorder.
    Hare HH; Mahendraker N; Sarwate S; Tangella K
    Cutis; 2008 Oct; 82(4):252-6. PubMed ID: 19055168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microsatellite instability in Muir-Torre syndrome.
    Honchel R; Halling KC; Schaid DJ; Pittelkow M; Thibodeau SN
    Cancer Res; 1994 Mar; 54(5):1159-63. PubMed ID: 8118799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Muir-Torre syndrome].
    Körber J; Djawari D
    Hautarzt; 2001 Dec; 52(12):1107-10. PubMed ID: 11910863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of microsatellite instability in unselected sebaceous gland neoplasias and hyperplasias.
    Kruse R; Rütten A; Schweiger N; Jakob E; Mathiak M; Propping P; Mangold E; Bisceglia M; Ruzicka T
    J Invest Dermatol; 2003 May; 120(5):858-64. PubMed ID: 12713593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of functional testing in the genetic assessment of Muir-Torre syndrome, a clinical subphenotype of HNPCC.
    Ollila S; Fitzpatrick R; Sarantaus L; Kariola R; Ambus I; Velsher L; Hsieh E; Andersen MK; Raevaara TE; Gerdes AM; Mangold E; Peltomäki P; Lynch HT; Nyström M
    Int J Oncol; 2006 Jan; 28(1):149-53. PubMed ID: 16327991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Muir-Torre syndrome].
    Yoshikawa R; Utsunomiya J
    Nihon Rinsho; 1995 Nov; 53(11):2803-6. PubMed ID: 8538048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic MMR gene mutations as a cause for MSI-H sebaceous neoplasms in Muir-Torre syndrome-like patients.
    Joly MO; Attignon V; Saurin JC; Desseigne F; Leroux D; Martin-Denavit T; Giraud S; Bonnet-Dupeyron MN; Faivre L; Auclair J; Grand-Masson C; Audoynaud C; Wang Q
    Hum Mutat; 2015 Mar; 36(3):292-5. PubMed ID: 25504677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemistry screening of sebaceous lesions for Muir-Torre syndrome in a 26-year period in a Mexican population.
    Archer-Dubon C; Alvarez-Zavala B; Reyes E; Orozco-Topete R
    Dermatol Online J; 2008 Dec; 14(12):1. PubMed ID: 19265614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sebaceous lesions and their associated syndromes: part II.
    Eisen DB; Michael DJ
    J Am Acad Dermatol; 2009 Oct; 61(4):563-78; quiz 579-80. PubMed ID: 19751880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muir-Torre syndrome and recent updates on screening guidelines: The link between colorectal tumors and sebaceous adenomas in unusual locations.
    Shaker N; Shaker N; Abid A; Shah S; Shakra RA; Sangueza OP
    J Surg Oncol; 2023 Dec; 128(8):1380-1384. PubMed ID: 37706607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Muir-Torre syndrome.
    Lachiewicz AM; Wilkinson TM; Groben P; Ollila DW; Thomas NE
    Am J Clin Dermatol; 2007; 8(5):315-9. PubMed ID: 17902735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.